MÃ©decins Sans FrontiÃ¨res vaccinate over 10 million people a year, primarily in regions affected by outbreaks in measles, meningitis, cholera and yellow fever. In 2011 alone over 4 million people were vaccinated against measles in the Democratic Republic of Congo. The initial AMC concept was a financial mechanism conceived to act as a catalyst for the development of new vaccines and answering the issues of global health needs. Daniel Berman, Deputy Director of the MÃ©decins Sans FrontiÃ¨res Access Campaign compared existing and alternative AMC strategies at the World Vaccines Congress 2012 in Washington.
Why not download the full presentation and discover more about the alternate AMC Strategies available:
Â· The AMC was initially designed to stimulate R&D for products that would not have been developed otherwise. Is it also suited as an incentive to increase production capacity?
Â· Why was PCV-9 discontinued, and with hindsight, what could have been done differently to speed this product to market?
Â· Could the AMC have been designed to speed up availability of pneumococcal vaccine at a lower price to donors and countries? What are potential cost savings and increased numbers of children that could be reached?
Â· What would alternative strategies look like? Could there be room to customise approaches for companies with existing products versus companies with products in development?
Â· Considering opportunity costs for multinational companies, would an AMC to stimulate innovation â€˜give value for money'?